P.P.P.S. :-), April 2017 is when NICE formally introduces a new procedural system know as Abbreviated Technology Appraisal. This seems like a compromise between Normal appraisal timelines and Early Access to Medicine, because it is not quite as quick as EAMES, but it allows for early reimbursement. I'd say if ATA is an effective program, EAMES may be phased out. (P.P.P.P.S. Linda likes to be the first one through new programs. Just saying.)
As I noted to H2R... Dr. Prins is definitely presenting at AACR, and has no abstract associated with his presentation. It looks to be an education session he and others will speak at entitled: Cancer Immunology for the Non-Immunologist: Tutorial.
So Dr. Prins at AARC, and NWBO is there at least in their booth, and the company has used the spotlight exhibitions before at both these major oncology conferences.
News 
Market Data 
Discover 
